|
|
||||||||
J Thorac Cardiovasc Surg 2000;119:673-681
© 2000 The American Association for Thoracic Surgery
CARDIOTHORACIC TRANSPLANTATION |
From the Departments of Surgerya and Pathologyb and the Thomas E. Starzl Transplant Institute,c University of Pittsburgh, Pittsburgh, Pa.
Supported in part by the American College of Surgeons Faculty Fellowship, The Thoracic Surgery Research Foundation, American Heart Association grants to Si M. Pham, and National Institutes of Health grant AI40329 to John J. Fung and Abdul S. Rao.
Address for reprints: Si M. Pham, MD, Jackson Memorial Hospital, Highland Professional Bldg, 1801 NW 9th Ave, 5th Floor, Miami, FL 33136 (E-mail: spham{at}med.miami.edu ).
Background: Donor chimerism (the presence of donor cells of bone marrow origin) is present for years after transplantation in recipients of solid organs. In lung recipients, chimerism is associated with a lower incidence of chronic rejection. To augment donor chimerism with the aim to enhance graft acceptance and to reduce immunosuppression, we initiated a trial combining infusion of donor bone marrow with heart transplantation. Reported herein are the intermediate-term results of this ongoing trial.
Methods: Between September 1993 and August 1998, 28 patients received concurrent heart transplantation and infusion of donor bone marrow at 3.0 x 108 cells/kg (study group). Twenty-four contemporaneous heart recipients who did not receive bone marrow served as controls. All patients received an immunosuppressive regimen consisting of tacrolimus and steroids.
Results: Patient survival was similar between the study and control groups (86% and 87% at 3 years, respectively). However, the proportion of patients free from grade 3A rejection was higher in the study group (64% at 6 months) than in the control group (40%; P = .03). The prevalence of coronary artery disease was similar between the two groups (freedom from disease at 3 years was 78% in study patients and 69% in controls). Similar proportions of study (18%) and control (15%) patients exhibited in vitro evidence of donor-specific hyporesponsiveness.
Conclusions: The infusion of donor bone marrow reduces the rate of acute rejection in heart recipients. Donor bone marrow may play an important role in strategies aiming to enhance the graft acceptance.
This article has been cited by other articles:
![]() |
B. P. Griffith, M. Haddad, and R. S. Poston Immunobiology of Heart and Heart-Lung Transplantation Card. Surg. Adult, January 1, 2008; 3(2008): 1513 - 1538. [Full Text] |
||||
![]() |
J.-M. Dubernard, B. Lengele, E. Morelon, S. Testelin, L. Badet, C. Moure, J.-L. Beziat, S. Dakpe, J. Kanitakis, C. D'Hauthuille, et al. Outcomes 18 Months after the First Human Partial Face Transplantation N. Engl. J. Med., December 13, 2007; 357(24): 2451 - 2460. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. O. Taylor Cardiac transplantation: drug regimens for the 21st century Ann. Thorac. Surg., June 1, 2003; 75(90060): S72 - 78. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. P. Griffith and R. S. Poston Immunobiology of Heart and Heart-Lung Transplantation Card. Surg. Adult, January 1, 2003; 2(2003): 1403 - 1426. [Full Text] |
||||
![]() |
C. C. Canver and J. Chanda Heart transplantation Ann. Thorac. Surg., August 1, 2001; 72(2): 658 - 660. [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |